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Fragile X-associated tremor/ataxia syndrome (FXTAS) is an adult-onset inherited neurodegenerative disorder
characterized by intentional tremor, gait ataxia, autonomic dysfunction, and cognitive decline. FXTAS is caused by
the presence of a long CGG repeat tract in the 5′ UTR of the FMR1 gene. In contrast to Fragile X syndrome, in which
the FMR1 gene harbors over 200 CGG repeats but is transcriptionally silent, the clinical features of FXTAS arise from
a toxic gain of function of the elevated levels of FMR1 transcript containing the long CGG tract. However, how this
RNA leads to neuronal cell dysfunction is unknown. Here, we discuss the latest advances in the current
understanding of the possible molecular basis of FXTAS.Review
Introduction
Fragile X-associated tremor/ataxia syndrome (FXTAS) is
a neurodegenerative disorder that affects older adults who
have a large CGG-repeat tract in the 5′-untranslated re-
gion (UTR) of the Fragile X Mental Retardation 1 (FMR1)
gene [1]. Historically, carriers of Fragile X (FX) premuta-
tion alleles with 55 to 200 CGG repeats are considered at
risk for FXTAS. The prevalence of premutation alleles is
approximately 1 in 260 to 1 in 800 for males and 1 in 130-
to 1 in 250 for females in the general population [2,3].
Given reduced penetrance of FXTAS, it is estimated that 1
in 2,000 men over the age of 50 years in the general popula-
tion will show symptoms of FXTAS [2,4-6]. Clinical fea-
tures of FXTAS include progressive intention tremor and
gait ataxia, which is frequently accompanied by progressive
cognitive decline, parkinsonism, peripheral neuropathy, and
autonomic dysfunction [7]. The neuropathology of FXTAS
consists of mild brain atrophy and degeneration of the cere-
bellum, including hyperintensity of the middle cerebellar
peduncle (MCP), loss of Purkinje neuronal cells, spongiosis
of the deep cerebellar white matter, Bergman gliosis, and
swollen axons [8-10]. Immunocytochemical staining of* Correspondence: ncharlet@igbmc.fr
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unless otherwise stated.post-mortem brain tissue from FXTAS reveals the presence
of eosinophilic and ubiquitin-positive intranuclear inclu-
sions that are broadly distributed throughout the brain, in-
cluding in neurons and astrocytes [9,10], the spinal column,
and several non-nervous tissues including thyroid, heart,
and the Leydig cells in the testes [11,12].
In contrast to the absence of FMR1 mRNA and protein
expression seen in carriers of a full mutation (over 200
CGG repeats), individuals with premutation alleles have
markedly increased expression of FMR1 mRNA, but only
moderately decreased FMRP levels [13-16]. FXTAS is not
seen in carriers of fully silenced FMR1 alleles, suggesting
that a novel mechanism, involving increased expression of
the long CGG repeat tract in the FMR1 mRNA, is respon-
sible for FXTAS. In support of this hypothesis, multiple
studies have demonstrated adverse consequences of
expressing CGG repeats in fly, mouse, and cell models
[17-22]. Consistent with an RNA-based pathological
mechanism, FXTAS has also been reported in individual
carriers of intermediate alleles (45 to 55 CGG repeats)
[23,24], and in full mutation allele carriers who are mo-
saics, both for repeat size and methylation, and who still
express some FMR1 mRNA [25-27]. In addition, there has
been a report documenting the presence of intranuclear
inclusions in the brains of three older adult males with
Fragile X syndrome (FXS) [12]. These results have impli-
cations for the spectrum of FX-associated disorders, and
suggest that the definition of FXTAS may need to betd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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spective of its size, makes sufficient RNA for its deleteri-
ous effects to be apparent.
How the RNA containing expanded CGG repeats leads
to FXTAS pathogenesis is not yet fully known. This re-
view will cover the recent advances in the understanding
of the molecular mechanisms that may contribute to the
pathogenesis of FXTAS, including the data presented at
the First International Conference on FMR1 Premuta-
tion (23 to 26 June, Perugia, Italy). For other aspects of
FXTAS, there are a number of excellent reviews available
[28-31], as well the additional articles published in this
special issue of JND.
CGG repeats are unstable, and tend to expand over time
or with successive generations
Increased CGG repeat numbers are associated with an
increased risk of FXTAS and with an increased severity
and reduced age of onset of FXTAS symptoms [5,6]. The
CGG repeat tract responsible for FXTAS is polymorphic
in the human population. Normal alleles have between 6
and 45 repeats, and are relatively stable on intergener-
ational transmission. However, as the repeat number
increases, so too does the likelihood that the repeat
tract will expand or gain additional repeat units on in-
tergenerational transfer. AGG interruptions, which are
commonly seen within FMR1 alleles, typically at 10 to
11 and 20 to 21 triplets from the 5′ end [32], are associated
with a reduced risk of expansion [33,34]. Contractions
do occur [35], but much less frequently. One of the con-
sequences of the expansion bias is that alleles tend to
increase in repeat number with successive generations.
In addition to intergenerational expansion, somatic ex-
pansion is also seen in certain organs, including the
brain in mice, and both lymphocytes and brain tissue in
humans [27,36]. Somatic expansion may contribute to the
repeat-length mosaicism that is seen in some human pre-
mutation carriers [27,37-40]. This somatic expansion has
the potential to exacerbate FXTAS symptoms, particularly
in carriers of alleles with more than 100 CGG repeats,
where the repeat may be particularly prone to expansion.
The mechanism responsible for these expansions is
unknown. A number of other diseases are known to result
from expansions of tracts containing these repeats or other
short repeat units. Whether or not these diseases, which
are referred to collectively as the repeat expansion diseases
[41], share a common expansion mechanism is unknown.
However, the unusual nature of these mutations suggests
that they might. The expansion bias clearly differentiates
the instability in these diseases from the classic microsatel-
lite instability seen in certain cancers, where the repeat is as
likely to lose repeats as it is to gain them.
The individual strands of expanded CGG repeats, like
other repeats that cause repeat expansion diseases, formsecondary structures, including hairpins and quadruplexes
[42]. These structures affect DNA processing enzymes
such as DNA polymerase, both in vitro [42] and in vivo
([43,44]. It is generally thought that these structures are
the trigger or substrate for expansion [41]. However,
expansion in brain and liver, which are organs with a low
proliferative capacity, along with expansion in mouse oo-
cytes [45,46], suggest that the expansion mechanism may
not involve aberrant DNA replication. Rather, given that
oxidative stress exacerbates expansion in mice [47], it may
be that expansion results from the aberrant repair of oxi-
dized DNA or of DNA that is damaged in other ways. In
contrast to generalized microsatellite instability, expansion
in premutation mice actually requires Msh2 [48]. However,
whether expansion involves disruption of classic mismatch
repair or involves another MSH2-dependent process is un-
known. Although Msh2 is required for expansion, it is not
required for contractions [45,46,48]. Thus, it seems likely
that expansions and contractions occur by different mecha-
nisms, and the expansion bias seen in FX pedigrees may
reflect a more efficient operation of the expansion process
relative to the process that generates contractions.
Expression of FMR1 mRNA is increased in
premutation carriers
Several studies have shown that premutation alleles are
characterized by high mRNA expression levels [13,15,16,49].
In our recent analysis, FMR1 gene expression levels were
measured in peripheral blood leukocytes from a total of 806
males across the whole range of CGG repeats, including
normal individuals (n = 463), and individuals carrying inter-
mediate (n = 60) and premutation (n = 283) alleles [27]. The
results showed that FMR1 mRNA levels increased with in-
creased CGG repeat number, and that a significant increase
(P < 0.001) was detectable for allele lengths as short as
35 CGG repeats (Figure 1). In addition, nuclear run-on
experiments indicated that this elevated level of FMR1
mRNA in premutation carriers is caused by increased
transcription efficiency rather than increased mRNA sta-
bility [14,15]. Despite higher levels of FMR1 transcripts,
mild deficits of FMRP have been found in premutation
carriers, and are probably due to a deficit in translational
efficiency, particularly in the upper premutation range
[13,16,49]. Thus, an FMRP deficiency is probably not the
principal cause of FXTAS. Instead, the crucial observation
that RNAs containing expanded CGG repeats accumulate
in nuclear RNA aggregates in brain sections of patients
with FXTAS [50] supports the notion that elevated levels
of FMR1 mRNA trigger neuronal toxicity. In support of
this hypothesis, heterologous expression of 90 CGG re-
peats in Drosophila melanogaster was shown to cause
neurodegeneration and formation of ubiquitin inclusions
[18]. Similarly, a knock-in (KI) mouse model, in which the
endogenous eight CGG repeats of the murine Fmr1 were
Figure 1 Quantification of FMR1 mRNA levels in the three allele
categories (normal, intermediate, and premutation) shows that
FMR1 mRNA expression increases significantly with increasing
CGG repeat number. The solid blue line on the plot shows a
piecewise linear regression fit, with FMR1 mRNA expression increased
significantly in all three groups (P = 0.012, P < 0.001, and P < 0.001 for
normal, intermediate, and premutation carriers, respectively).
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repeats of human origin, showed ubiquitin-positive nuclear
inclusions, and mild neuromotor and behavioral dis-
turbances [17,51,52]. Finally, expression of transcripts
containing 90 CGG repeats in a transgenic mouse
model recapitulated some of the neuropathological and
molecular features of FXTAS, despite the presence of a
normal Fmr1 allele [19] (see also review on animal
models for FXTAS in this issue). These animal models
show that the expression of FMR1 mRNA containing
expanded CGG repeats is both necessary and sufficient
to cause pathological features characteristic of human
FXTAS. Several mechanisms have been proposed to
explain how increased expression of a RNA containing
expanded CGG repeats could be pathogenic.
Is pathology the result of an RNA gain-of-function
mechanism?
The first recognized examples of RNA gain-of-function
diseases were two other repeat expansion diseases,
myotonic dystrophy type 1 and 2 (DM1 and DM2) [53].
DM is the most common muscular dystrophy in adults,
and in this condition, RNAs containing hundreds to
thousands of CUG (DM1) or CCUG (DM2) repeats ac-
cumulate in nuclear RNA aggregates that sequester the
Muscleblind-like (MBNL) splicing factors. Depletion of
the free pool of MBNL1 leads to specific alternative
splicing changes, which ultimately result in the symptoms
of DM [53]. Extending this RNA gain-of-function model
to FXTAS, the expanded CGG repeats are predicted tosequester specific proteins, resulting in loss of their normal
functions, which would ultimately cause the symptoms of
FXTAS [54,55]. Consistent with this idea, Iwahashi and
collaborators [56] identified more than 20 proteins from
inclusions purified from brains of patients with FXTAS.
Of these, two RNA binding proteins were of special inter-
est. The first, hnRNP A2/B1 is mutated in families with
inherited degeneration affecting muscle, brain, bone, and
motor neurons [57], while the second, MBNL1, is the spli-
cing factor that is involved in DM [58]. However, a role
for MBNL1 in FXTAS has been excluded, because no gen-
etic interaction between MBNL1 and CGG-mediated neu-
rodegeneration was observed in the fly model of FXTAS
[59], and no misregulation of splicing events regulated by
MBNL1 was observed in brain samples from patients with
FXTAS [60]. By contrast, binding of hnRNP A2/B1 to
RNA containing expanded CGG repeats was confirmed
by independent proteomic and in vitro analyses [60,61].
Furthermore, overexpression of hnRNP A2/B1 rescued
the neurodegeneration in transgenic Drosophila express-
ing 90 CGG repeats [59,61]. Interaction of hnRNP A2/B1
with RNA containing expanded CGG repeats was evident
in cytoplasmic cerebellar lysates. By contrast, nuclear
hnRNP A2/B1 presented little binding to CGG RNA,
suggesting that some modifications of hnRNP A2/B1,
either in the nucleus or in the cytoplasm, may alter the
ability of hnRNP A2/B1 to bind to CGG RNA repeats
[59]. The importance of titration of the cytoplasmic
pool of hnRNP A2/B1 was further demonstrated by ex-
pression of expanded CGG repeats in primary cultures
of rat sympathetic neurons [62]. RNA containing CGG
repeats competed for binding of hnRNP A2/B1 to BC1
RNA, a dendritic regulatory RNA, resulting in impaired
dendritic delivery of the BC1 RNA [62]. However, no mis-
regulation of splicing events regulated by nuclear hnRNP
A2/B1 was observed in brain samples of patients with
FXTAS [60]. Overall, these data suggest that expanded
CGG repeats recruit hnRNP A2/B1, resulting in depletion
of the cytoplasmic but not the nuclear pool of hnRNP
A2/B1. In addition, the ability of hnRNP A proteins to
unfold tetraplex RNA structures, formed by expanded
CGG repeats [63,64], raises the possibility that hnRNP
A2/B1 may also act as a RNA chaperone that destabi-
lizes these RNA structures. Finally, Sofola and collabo-
rators [59] demonstrated that hnRNP A2/B1 recruits,
in trans and through protein-protein interactions,
other proteins such as CUGBP1, an RNA binding protein,
whose expression is increased in heart samples of patients
with DM [65]. These data indicated that proteins binding
to CGG RNA may recruit other proteins, resulting in dy-
namic aggregates that expand over time, a model later
confirmed in COS7 cells expressing 60 CGG repeats [60].
Overexpression of either hnRNP A2/B1 or CUGBP1 res-
cued neurodegeneration in a Drosophila model of FXTAS,
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and CUGBP1 to FXTAS pathology [59].
In addition to hnRNP A2/B1, proteomic analyses
performed by Jin and collaborators [61] also showed
that purine-rich binding protein α (Purα) binds ro-
bustly to RNA containing expanded CGG repeats. Purα
is a single-stranded cytoplasmic DNA and RNA bind-
ing protein that has been implicated in many biological
processes, including RNA transport and translation.
Importantly, overexpression of Purα rescued neurodegen-
eration in a Drosophila model of FXTAS [61]. However,
presence of Purα within nuclear aggregates in FXTAS
brain samples is inconsistently observed. Jin et al. found
Purα in cytoplasmic inclusions in Drosophila expressing
90 CGG repeats, and in inclusions in superior-mid tem-
poral cortex neurons from human FXTAS brain sections
[61]. By contrast, Iwashashi et al. did not detect Purα in
purified inclusions from cerebral cortex of patients with
FXTAS [56]. Furthermore, Purα-positive inclusions have
not been observed in mouse models of FXTAS [66], or in
hippocampal and cortical brain section of patients with
FXTAS [67]. These results suggest that the composition of
the inclusions varies from one brain region to the next
and from one model organism to the other. Analogous to
the recruitment of CUGBP1 by hnRNP A2/B1 to RNA
containing expanded CGG repeats, Purα was shown to
recruit Rm62, the Drosophila ortholog of the RNA heli-
case P68/DDX5 [68]. Expression of expanded CGG repeats
resulted in the post-transcriptional downregulation of
Rm62, ultimately resulting in nuclear accumulation of
Hsp70 mRNA and of other mRNAs involved in stress
and immune responses [68]. Overexpression of Rm62
rescued neurodegeneration in flies expressing 90 CGG
repeats, highlighting the potential importance of P68/DDX5
to FXTAS pathology [68].
SAM68, a splicing regulator encoded by the KHDRBS1
gene, was also found in CGG RNA aggregates [60]. How-
ever, overexpression of SAM68 was not sufficient to rescue
neuronal cell death induced by expression of expanded
CGG repeats [67]. As with CUGBP1 and Rm62, SAM68
did not bind directly to CGG repeats, and recruitment
of SAM68 within CGG RNA aggregates occurred in trans
through protein-protein interactions [59]. Sellier and
collaborators [67] also showed that DROSHA-DGCR8,
the enzymatic complex that processes pri-microRNAs
into pre-miRNAs, associated specifically with CGG repeats
of pathogenic size. Sequestration of DROSHA-DGCR8
within CGG RNA aggregates resulted in reduced pro-
cessing of pri-miRNAs in cells expressing expanded
CGG repeats, and in brain samples from patients with
FXTAS. Overexpression of DGCR8 rescued neuronal
cell death induced by expression of expanded CGG
repeats [67]. These results suggest that titration of
DGCR8 by expanded CGG repeats is a leading eventto CGG-induced neuronal cell death. However, recent
analyses of miRNA expression in blood samples of patients
with FXTAS and in Drosophila expressing CGG repeats did
not show a global downregulation of miRNA, but rather,
the expression of some specific miRNAs was misregulated
[69,70]. Whether depletion of DROSHA-DGCR8 varies in
blood and brain of patients with FXTAS, and whether the
Drosha-Pasha complex is sequestered in cytoplasmic ag-
gregates in Drosophila expressing expanded CGG repeats,
remains to be determined. Similarly, whether overexpres-
sion of hnRNP A2/B1, P68/DDX5, DROSHA-DGCR8,
or CUGBP1 rescues any phenotype in mouse models
expressing expanded CGG repeats, would be necessary
to determine the importance of these candidate proteins
to FXTAS pathology.
These caveats aside, the observations described above
suggest that CGG repeats could be pathogenic by seques-
tering specific RNA binding proteins, resulting in loss of
their normal functions, and thus lead to neuronal cell dys-
function (Figure 2) [56,58,61,67,68]. However, this attractive
model has some weaknesses. First, the inclusions observed
in FXTAS brain sections differ from those seen in DM,
a typical RNA gain-of-function disorder. In FXTAS, in-
clusions are larger and ubiquitinated, and contain
various chaperone proteins such as Hsp27, Hsp70, and
αB-crystallin [9,56]. In short, these large inclusions resem-
ble the aggregates seen in protein-mediated disorders,
although they are negative for the typical proteins found
in tauopathies, synucleinopathies, or polyQ disorders
(for example, Huntington’s disease). Second, and most
disconcerting, although inclusions in brain samples of
patients with FXTAS contain the mutant FMR1 RNA
with expanded CGG repeats [50], a mouse model, in which
the endogenous eight CGG repeats of Fmr1 is replaced
with an expansion containing around 100 CGG repeats,
shows numerous ubiquitin inclusions but only rare aggre-
gates of SAM68 or DROSHA-DGCR8, associated with
rare RNA aggregates of expanded CGG repeats [60,67].
Similarly, overexpression of expanded CGG repeats leads
to formation of nuclear RNA aggregate in some cell types,
including primary cultures of hippocampal embryonic
mouse neurons and PC12, COS7, and SKOV3 immortal-
ized cell lines, but no RNA aggregates have been observed
in A172, U-937, THP1, HeLa, HEK293, NG108-15,
IMR-32, Neuro-2a, SH-SY5Y, SK-N-MC, or SK-N-SH
cells [22,60]. In short, not all cell lines can support
CGG repeat aggregate formation, whereas in DM, ex-
pression of expanded CUG or CCUG repeats consistently
results in formation of RNA foci. Thirdly, a recent and
provocative study demonstrates that the toxic effect of
CGG repeats depends on their location [71]. Moving
expanded CGG repeats from a 5′ UTR to a 3′ UTR
position reduced their toxic effect in Drosophila,
whereas expanded CUG or CCUG repeats were found
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Figure 2 Various RNA binding proteins have been found to associate with RNAs containing expanded CGG repeats. Purα, DGCR8, and
hnRNP A2/B1 bind directly to the CGG-containing RNA, whereas Rm62, SAM68, and CUGBP1 are recruited in trans through protein-protein
interactions.
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they were expressed in sufficient amounts to deplete
MBNL proteins. These data led Todd and collaborators to
reconsider the model of RNA binding protein sequestra-
tion, and to explore further the molecular mechanisms
of FXTAS.
Non-canonical AUG translation produces a
polyglycine-containing protein in FXTAS
An unexpected observation, made by Todd and colleagues
in flies transgenic for a construct containing 90 expanded
CGG repeats cloned upstream of the green fluorescent
protein (GFP) cDNA, was that some of the GFP signal
was found in cytoplasmic inclusions. Western blotting
analysis showed a band of the expected size for GFP, but
also detected a protein 12 kDa larger [71]. Because trans-
lation of expanded CAG repeats in the absence of an ATG
initiation codon (repeat-associated non-ATG translation
or RAN translation) had been previously reported [72],
Todd and collaborators tested whether expanded CGG
repeats could be translated despite the fact that no ATG
codon is present upstream of the repeats. Their analysis
revealed that, indeed, translation of CGG repeats occurs
in two out of the three frames, giving rise to short proteins
containing either a polyalanine or a polyglycine stretch.
Expression of the polyglycine protein resulted in the for-
mation of protein inclusions, which were toxic both in
neuronal transfected cells and in Drosophila. Further ana-
lyses of the polyglycine protein revealed that its translation
was probably initiated at non-canonical AUG codons,
such as CUG and GUG, which were located upstream ofthe CGG repeats. A role for non-canonical translation ini-
tiation in inclusion formation is consistent with data from
two different KI mice mouse models. In a mouse model
that showed numerous ubiquitin inclusions, the expanded
CGG repeat from a human premutation allele was cloned,
along with sequences upstream of the CGG repeats in
humans that contained the non-AUG initiations codons
[17]. By contrast, in a second mouse model, in which the
mouse 5′ flanking sequence was retained, a stop codon
was found to be located just upstream of the expanded
CGG repeats [21]. These latter mice showed relatively few
ubiquitinated aggregates, thus supporting the notion that
non-ATG-initiated translation of the CGG tract is required
to generate most of the inclusions [71]. That this unusual
mode of translation may play a role in FXTAS is evidenced
by the fact that, with the aid of specific antibodies, polygly-
cine protein can be seen in brain sections of patients with
FXTAS [71]. Overall, these observations suggest that a
protein gain of function may also occur in cells of patients
with FXTAS. However, what contribution the polyglycine-
containing or polyalanine-containing proteins make to the
etiology of FXTAS is an exciting open question.
Non-coding transcription of the FMR1 locus: a role in
FMR1 mRNA toxicity?
The majority of the human genome is transcribed but
not translated. Such RNAs are classified as long non-
coding RNAs (lncRNAs) when longer than 200 nucleo-
tides [73-75]. To date, relatively few lncRNAs have been
functionally characterized, but increasing evidence sug-
gests that many may have important functions, including
Sellier et al. Journal of Neurodevelopmental Disorders 2014, 6:23 Page 6 of 10
http://www.jneurodevdisorders.com/content/6/1/23the regulation of transcription, RNA processing and trans-
lation, DNA methylation, and chromatin architecture,
both locally (cis-acting) and across some genomic distance
(trans-acting) [76-78].
In addition to the FMR1 transcript, a variety of RNAs
are produced from the FMR1 locus. Therefore, it is pos-
sible that these lncRNAs produced from the FMR1 locus
may modulate certain aspects of FXS/FXTAS, as has
been shown in other human diseases [79]. For example,
Kumari and Usdin described an abundant antisense
transcript of about 5 kb that spans the region upstream
of the FMR1 promoter, and whose expression does not
change in response to repeat expansion [80]. By contrast
Ladd and coworkers described a transcript, Antisense
FMR1 (ASFMR1), that spans the expanded CGG repeats
and whose expression is elevated in lymphoblastoid cells
and peripheral blood leukocytes of individuals with pre-
mutation alleles, while it is not expressed in those with full
mutation alleles [81]. Multiple splice forms of ASFMR1
have been identified, which show differential expression in
carriers of premutation and normal alleles [81]. One of
these ASFMR1 splice variants contains a small intron that
uses a non-consensus CT-AC splice site that is transcribed
in a premutation cell line, but is absent in a normal cell line
[81]. We compared the expression levels of this ASFMR1
isoform in blood from individuals with alleles ranging from
normal to premutation, and found a significant increase
with CGG repeat number (P < 0.001) (Figure 3) [27]. Of
interest, both unspliced and spliced ASFMR1 transcripts
contain putative open-reading frames encoding polyproline
peptides, resulting from antisense-oriented translation ofFigure 3 Expression of the minor splice isoform in the ASFMR1
transcript (131 bp), located near the ASFMR1 promoter.
Expression of this isoform increases in premutation carriers (P < 0.001),
and shows a similar trend in subjects with intermediate alleles
(P = 0.0528) compared with normal alleles. The solid blue line on the
plot shows a piecewise linear regression fit (fitted on the log scale
then exponentiated for plotting), with separate slopes in the normal,
intermediate, and premutation alleles.the expanded CGG repeats [81]. Whether ASFMR1
containing expanded CCG repeats is translated and
participates in the formation of the pathogenic nuclear
inclusions observed in patients with FXTAS remain to
be tested.
Another antisense transcript, FMR4, originates upstream
of the FMR1 start site, and covers 2.4 kb of sequence [82].
FMR4 is widely expressed in fetal and adult human tissues,
and throughout human and macaque brain regions.
Expression of FMR4, like that of ASFMR1 and FMR1,
is increased in brain tissue of premutation individuals
and is silenced in individuals with the full mutation
[82]. Importantly, FMR4 overexpression was shown to
increase cell proliferation, whereas FMR4 downregula-
tion induced apoptosis in vitro [82]. Additionally, no
cis-acting effect was observed upon expression of the
FMR1 gene. Therefore, it was hypothesized that FMR4
influences proliferation pathways in trans, by targeting
distal genomic loci. Current work is focused on defin-
ing a role for this transcript, as it has been found to
affect the chromatin state and transcription of several
genes involved in neuronal differentiation, axon guidance,
and synaptic signaling, as well as cell cycle regulators
(Peschansky and Pastori, unpublished data).
Two new transcripts arising from the FMR1 locus,
FMR5 and FMR6, were recently identified [83]. FMR5 is
a sense-oriented lncRNA transcribed from approximately
1 kb upstream of the FMR1 transcription start site (TSS).
FMR5 is not differentially expressed in human brain from
unaffected individuals compared with full mutation and
premutation patients, suggesting that its transcription is
independent of CGG repeat expansion. Furthermore, the
TSS of FMR5 appears not to be affected by the chromatin
silencing that occurs within full mutation alleles, or by the
open chromatin hypothesized to increase transcription of
FMR1 premutation alleles. FMR6 is a spliced long anti-
sense transcript, 600 nucleotides i, whose sequence is en-
tirely complementary to the 3′ region of FMR1 [83]. It
begins in the 3′UTR, ends in exon 15 of FMR1, and uses
the same splice junctions as FMR1. An unexpected finding
was that FMR6 is reduced in premutation carriers, sug-
gesting that abnormal transcription and/or chromatin re-
modeling occurs toward the distal end of the locus.
However, the chromatin marks associated with the 3′ end
of FMR1 in premutation carriers have yet to be described.
The function of FMR6 remains to be identified, but its
complementarity to the 3′ region of FMR1 presents
several interesting possibilities. FMR6 may bind to FMR1
mRNA, thereby regulating the stability, splicing, subcellular
localization, or translational efficiency of FMR1, as has been
described for other lncRNAs [77]. Notably, FMR6 overlaps
miR-19a and miR-19b binding sites in the FMR1 3′ UTR
[84], suggesting that FMR6 may modulate the stability
or translational efficiency of FMR1 by interfering with
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importance of non-coding transcription of the FMR1
locus. However, much work remains to fully understand
the relevance of these transcripts to the pathology observed
in premutation carriers.
Conclusion
The restriction of FXTAS clinical features to unmethylated,
transcriptionally active alleles with large CGG repeat num-
bers suggests that the expression of a mutant RNA is
pathogenic to neuronal cells [55]. This hypothesis is sup-
ported by data from cell, fly, and mouse models [17-22].
However, how these RNAs cause neuronal cell dysfunction
and FXTAS symptoms remains unclear. One model pro-
poses that the RNA containing expanded CGG repeats is
pathogenic via its sequestration of specific RNA binding
proteins. Various proteins, including Purα, Rm62, CUGBP1,
hnRNP A2/B1, SAM68, and DROSHA-DGCR8, have been
shown to bind directly or through a protein partner to ex-
panded CGG repeats [56,59,61,67,68]. However, it remains3 60<CGG<200 
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Figure 4 Mechanisms that may contribute to fragile X-associated trem
associated antisense transcripts are increased inpremutation carriers. Some
proteins, while export and non-AUG translation results in production of poto be tested whether overexpression of these candidate
proteins rescues any phenotype in mouse models ex-
pressing expanded CGG repeats. A second mechanism
involves non-canonical translation initiation of expanded
CGG repeats. resulting in expression of toxic polyglycine-
containing and polyalanine-containing proteins [71]; how-
ever, how these proteins promote neuronal cell dysfunction
is an open question. A third model is associated with the
expression of antisense FMR1 transcripts. Further investiga-
tion is needed to evaluate the pathological consequences
of expression of ASFMR1 or other long non-coding RNA
mapping within the FMR1 gene. Finally, although de-
creased expression of FMRP is probably not the principal
cause of FXTAS, it cannot be excluded that a reduction in
FMRP plays a role in modulating some of FXTAS features.
In that context, the level of FMRP depletion in brain sam-
ples from a larger cohort of patients with FXTAS needs to
be measured.
In conclusion, in addition to increased FMR1 mRNA
production, protein titration, non-AUG translation,SAM68 
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or/ataxia (FXTAS) pathology. Expression of FMR1 mRNA and
transcripts accumulate in the nucleus and recruit various RNA binding
lyglycine-containing or polyalanine-containing proteins.
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http://www.jneurodevdisorders.com/content/6/1/23antisense transcription, and decreased expression of
FMRP are a number of non-exclusive mechanisms
that may all contribute to FXTAS pathology. It is pos-
sible that contributions to pathology from more than
one mechanism may help to explain the great variabil-
ity in clinical presentation of premutation individuals,
aspects of which have heretofore not been accounted
for by CGG expansion size, mosaicism, methylation,
alternative spliced isoforms, additional genomic changes,
or other known factors. Thus, more work is needed to de-
termine the relative contribution of these processes to dis-
ease pathology in this multifaceted disorder (Figure 4).
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